- Cancer Risk: It’s Not a Straight Line
-
Stars at Night Ballroom B4‚ Convention Center
Chair: Anna Lowit, US EPA
Co-Chair: Gina Hilton, PETA Science Consortium International e.V., Germany
Primary Endorser: Risk Assessment Specialty Section
Endorser(s): Carcinogenesis Specialty Section
Endorser(s): Regulatory and Safety Evaluation Specialty SectionFor several decades, the default dose-response approach to evaluating carcinogenicity has been to conduct linear low-dose extrapolation using data from rodent bioassays and epidemiology studies. The International Programme on Chemical Safety (IPCS) of the World Health Organization mode of action (MOA)/human relevance framework and the US Environmental Protection Agency’s (EPA’s) Cancer Guidelines both describe an approach to establish a chemical’s MOA using data from new approach methods (NAMs), in vivo data, and human information where the key events are identified and evaluated using a weight of evidence approach considering a variety of factors including dose and time concordance and evaluating plausible alternative MOAs. For those cases where the MOA can be established for a particular chemical, the dose-response approach can move away from the default linear extrapolation, most often to non-linear or threshold extrapolation. Establishing an MOA requires several years of experimental study, often using large numbers of animals. Moreover, these approaches primarily apply to chemicals that do not cause direct-acting mutagenicity. While conservative, the no-threshold default approach continues despite growing biological evidence for cellular defense, repair, and adaptive responses. Both the IPCS MOA/human relevance framework and the US EPA’s Cancer Guidelines were developed in the early to mid-2000s and are thus 20+ years old. Given the explosion of omics data and other mechanistic and computational approaches that can provide broad information at low doses and that are specific to humans, is it time to reassess our approach to cancer risk assessment? This session will explore contemporary questions around cancer risk assessment --- Are we ready to go fully non-linear? Or does the science still support linearity? And if so, under what conditions or chemical properties? Specifically, this session will explore the state of the science regarding the biological processes underlying cancer, including the potential for mutagenicity. The first speaker will provide a historical perspective regarding cancer risk assessment and the origin of long-standing assumptions as context for the contemporary case studies provided in the remaining presentations. The second speaker will describe an analysis of over 400 pesticides to broadly consider MOA involved in chemical carcinogenesis and quantification of key events as part of an effort to move towards animal-free chemical risk assessment. The third speaker will describe case studies in which NAMs have been used to characterize cancer risk assessment using short-term transcriptomic points of departure and other mechanistic determinations for use in read-across and for pesticide degradates/metabolites. The fourth speaker will describe a novel non-linear method that considers dose-dependent toxicokinetics to support dose-response assessment for mutagenic carcinogens. The session will conclude with a panel discussion to explore regulatory implications and opportunities for alignment across jurisdictions, highlighting how NAM-enabled, mechanistically informed dose–response assessment can improve scientific credibility, efficiency, and animal welfare. The panel will be comprised of speakers and an academic expert experienced in transcriptomic-based MOA and implications in cancer risk assessment. Collectively, this session aims to advance practical pathways for modernizing non-genotoxic risk assessment while maintaining health-protective risk assessment and regulatory rigor.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
